2013
DOI: 10.1038/nri3581
|View full text |Cite
|
Sign up to set email alerts
|

Regulation of type I interferon responses

Abstract: Type I interferons (IFNs) activate intracellular antimicrobial programmes and influence the development of innate and adaptive immune responses. Canonical type I IFN signalling activates the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway, leading to transcription of IFN-stimulated genes (ISGs). Host, pathogen and environmental factors regulate the responses of cells to this signalling pathway and thus calibrate host defences while limiting tissue damage and preventing autoim… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

34
2,552
2
25

Year Published

2015
2015
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 2,626 publications
(2,613 citation statements)
references
References 138 publications
34
2,552
2
25
Order By: Relevance
“…In response to this binding signal, the JAK‐STAT pathway is activated, leading to transcriptional up‐regulation of the ISGs (Ivashkiv & Donlin, 2014; Schneider et al , 2014). Therefore, to show that the up‐regulated ISGs upon HNRNPC knock‐down depend on the interferon signaling cascade, we used an IFNβ antibody, an IFNAR2 blocking antibody, and the JAK‐STAT inhibitor ruxolitinib to block the interferon signaling pathway at different levels.…”
Section: Resultsmentioning
confidence: 99%
“…In response to this binding signal, the JAK‐STAT pathway is activated, leading to transcriptional up‐regulation of the ISGs (Ivashkiv & Donlin, 2014; Schneider et al , 2014). Therefore, to show that the up‐regulated ISGs upon HNRNPC knock‐down depend on the interferon signaling cascade, we used an IFNβ antibody, an IFNAR2 blocking antibody, and the JAK‐STAT inhibitor ruxolitinib to block the interferon signaling pathway at different levels.…”
Section: Resultsmentioning
confidence: 99%
“…In addition, VP24 prevents the nuclear accumulation of dimerized phosphorylated STAT-1 that participates in activation of both type I and type II signalling cascades [13,23,27]. It is possible that the negatively selected VP24 sites, 55 and 133, might aid the EBOV to become more pathogenic to human by inhibiting IFN response and blocking antigen presentation to T-cells [18].…”
Section: Discussionmentioning
confidence: 99%
“…Upon viral infection, virus components are recognized by host pattern recognition receptors (PRRs) including Toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) (Ivashkiv and Donlin, 2014). Such recognition events trigger distinct signaling pathways and finally activate the common transcription factors, mainly including IFN-regulatory factor 3 and/or 7, to initiate the transcription of type I IFNs.…”
Section: Introductionmentioning
confidence: 99%
“…Such recognition events trigger distinct signaling pathways and finally activate the common transcription factors, mainly including IFN-regulatory factor 3 and/or 7, to initiate the transcription of type I IFNs. The secreted type I IFNs exert their biological effects through induction of numerous IFNstimulated genes (ISGs) by the Janus kinase (Jak)-signal transducer and activator of the transcription (Stat) signaling pathway, where a transcription factor complex IFN-stimulated gene factor 3 (ISGF3) is formed, translocates to nucleus and specifically binds to the IFNstimulated response elements (ISREs) in the promoters of ISGs (Ivashkiv and Donlin, 2014). Although type I IFN response is essential for inhibition of viral infection, IFN overproduction is harmful to host and might result in several autoimmune diseases (Ivashkiv and Donlin, 2014).…”
Section: Introductionmentioning
confidence: 99%